NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. CASI, Booking Holdings Inc. BKNG, Enstar Group Limited ESGR, Madrigal Pharmaceuticals, Inc. MDGL, Dermira, Inc. DERM, and Kaiser Aluminum Corporation KALU, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
CASI DOWNLOAD: http://MarketSourceResearch.com/register/?so=CASI
BKNG DOWNLOAD: http://MarketSourceResearch.com/register/?so=BKNG
ESGR DOWNLOAD: http://MarketSourceResearch.com/register/?so=ESGR
MDGL DOWNLOAD: http://MarketSourceResearch.com/register/?so=MDGL
DERM DOWNLOAD: http://MarketSourceResearch.com/register/?so=DERM
KALU DOWNLOAD: http://MarketSourceResearch.com/register/?so=KALU
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine CASI Pharmaceuticals, Inc. CASI, Booking Holdings Inc. BKNG, Enstar Group Limited ESGR, Madrigal Pharmaceuticals, Inc. MDGL, Dermira, Inc. DERM, and Kaiser Aluminum Corporation KALU on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 26th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CASI PHARMACEUTICALS, INC. (CASI) REPORT OVERVIEW
CASI Pharmaceuticals' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, CASI Pharmaceuticals reported revenue of $0.00MM vs $0.00MM and analysts estimated basic earnings per share -$0.18 vs -$0.17. Analysts expect earnings to be released on April 4th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is -$0.23 and is expected to report on April 4th, 2019.
To read the full CASI Pharmaceuticals, Inc. (CASI) report, download it here: http://MarketSourceResearch.com/register/?so=CASI
-----------------------------------------
BOOKING HOLDINGS INC. (BKNG) REPORT OVERVIEW
Booking's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Booking reported revenue of $4,849.09MM vs $4,434.03MM (up 9.36%) and analysts estimated basic earnings per share $37.39 vs $35.12 (up 6.46%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Booking reported revenue of $12,681.08MM vs $10,743.01MM (up 18.04%) and analysts estimated basic earnings per share $47.78 vs $43.14 (up 10.76%). Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $16.86. The estimated EPS forecast for the next fiscal year is $101.52 and is expected to report on February 26th, 2019.
To read the full Booking Holdings Inc. (BKNG) report, download it here: http://MarketSourceResearch.com/register/?so=BKNG
-----------------------------------------
ENSTAR GROUP LIMITED (ESGR) REPORT OVERVIEW
Enstar Group's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Enstar Group reported revenue of $295.30MM vs $241.40MM (up 22.33%) and analysts estimated basic earnings per share -$0.74 vs $2.01. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Enstar Group reported revenue of $1,106.86MM vs $1,131.00MM (down 2.13%) and analysts estimated basic earnings per share $16.06 vs $13.72 (up 17.06%). Analysts expect earnings to be released on February 27th, 2019. The report will be for the fiscal period ending December 31st, 2018.
To read the full Enstar Group Limited (ESGR) report, download it here: http://MarketSourceResearch.com/register/?so=ESGR
-----------------------------------------
MADRIGAL PHARMACEUTICALS, INC. (MDGL) REPORT OVERVIEW
Madrigal Pharmaceuticals' Recent Financial Performance
Analysts expect earnings to be released on March 12th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is -$3.61 and is expected to report on March 12th, 2019.
To read the full Madrigal Pharmaceuticals, Inc. (MDGL) report, download it here: http://MarketSourceResearch.com/register/?so=MDGL
-----------------------------------------
DERMIRA, INC. (DERM) REPORT OVERVIEW
Dermira's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Dermira reported revenue of $0.72MM vs $1.07MM (down 32.74%) and analysts estimated basic earnings per share -$1.58 vs -$4.30. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Dermira reported revenue of $4.54MM vs $22.59MM (down 79.89%) and analysts estimated basic earnings per share -$7.48 vs -$2.70. Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$1.34. The estimated EPS forecast for the next fiscal year is -$5.43 and is expected to report on February 28th, 2019.
To read the full Dermira, Inc. (DERM) report, download it here: http://MarketSourceResearch.com/register/?so=DERM
-----------------------------------------
KAISER ALUMINUM CORPORATION (KALU) REPORT OVERVIEW
Kaiser Aluminum's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Kaiser Aluminum reported revenue of $393.10MM vs $332.80MM (up 18.12%) and analysts estimated basic earnings per share $1.31 vs $1.18 (up 11.02%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Kaiser Aluminum reported revenue of $1,397.50MM vs $1,330.60MM (up 5.03%) and analysts estimated basic earnings per share $2.67 vs $5.15 (down 48.16%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.22. The estimated EPS forecast for the next fiscal year is $7.45 and is expected to report on February 20th, 2019.
To read the full Kaiser Aluminum Corporation (KALU) report, download it here: http://MarketSourceResearch.com/register/?so=KALU
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com
© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
